Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary <i>SDN1-BRAF</i> fusion: A case report and literature review. This evidence concerns the gene MAP2K7 and lung adenocarcinoma.